FDA Clearance Tracker · K231336
T2 Biothreat Panel
Last checked: Nov 20, 2026Latest source record: Sep 15, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Sep 15, 2023
Substantially Equivalent
Time to decision
130 days
Received May 8, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K231336
- Device name
- T2 Biothreat Panel
- Applicant
- T2biosystems, Inc.
- Applicant location
- Lexington, MA
- Received
- May 8, 2023
- Decided
- Sep 15, 2023
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.4000
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QVR. The earliest in FDA's data is K213362, decided Mar 22, 2023.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K231336
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for T2biosystems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- T2Candida 1.1 Panel510(k)
K234063 · Decided Sep 13, 2024 · 266 days after receipt
Device type: Candida Species Nucleic Acid Detection System (PII) · Laboratory Medicine & Pathology
- T2Bacteria® Panel510(k)
K233184 · Decided Feb 8, 2024 · 133 days after receipt
Device type: Direct Blood Bacterial Nucleic Acid Detection System (QBX) · Laboratory Medicine & Pathology
- T2Bacteria Panel510(k)
K172708 · Decided May 24, 2018 · 258 days after receipt
Device type: Direct Blood Bacterial Nucleic Acid Detection System (QBX) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.